Literature DB >> 11683248

The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase.

L Lu1, F Leonessa, M T Baynham, R Clarke, F Gimenez, Y T Pham, F Roux, I W Wainer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683248     DOI: 10.1023/a:1013098213770

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  11 in total

1.  Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine.

Authors:  C D Riffkin; R Chung; D M Wall; J R Zalcberg; A F Cowman; M Foley; L Tilley
Journal:  Biochem Pharmacol       Date:  1996-11-22       Impact factor: 5.858

2.  Mutually co-operative interactions between modulators of P-glycoprotein.

Authors:  Y M Shao; S Ayesh; W D Stein
Journal:  Biochim Biophys Acta       Date:  1997-02-27

3.  Development of an immobilized P-glycoprotein stationary phase for on-line liquid chromatographic determination of drug-binding affinities.

Authors:  Y Zhang; F Leonessa; R Clarke; I W Wainer
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-02-28

4.  On the mechanism for the red-cell accumulation of mefloquine, an antimalarial drug.

Authors:  R C San George; R L Nagel; M E Fabry
Journal:  Biochim Biophys Acta       Date:  1984-03-23

5.  Stereoselective passage of mefloquine through the blood-brain barrier in the rat.

Authors:  S Baudry; Y T Pham; B Baune; S Vidrequin; C Crevoisier; F Gimenez; R Farinotti
Journal:  J Pharm Pharmacol       Date:  1997-11       Impact factor: 3.765

6.  Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT.

Authors:  Y T Pham; A Régina; R Farinotti; P Couraud; I W Wainer; F Roux; F Gimenez
Journal:  Biochim Biophys Acta       Date:  2000-12-15

7.  Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase.

Authors:  L Lu; F Leonessa; R Clarke; I W Wainer
Journal:  Mol Pharmacol       Date:  2001-01       Impact factor: 4.436

8.  Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria.

Authors:  Y T Pham; F Nosten; R Farinotti; N J White; F Gimenez
Journal:  Int J Clin Pharmacol Ther       Date:  1999-01       Impact factor: 1.366

9.  Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators.

Authors:  D F Tang-Wai; S Kajiji; F DiCapua; D de Graaf; I B Roninson; P Gros
Journal:  Biochemistry       Date:  1995-01-10       Impact factor: 3.162

10.  MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.

Authors:  F Leonessa; D Green; T Licht; A Wright; K Wingate-Legette; J Lippman; M M Gottesman; R Clarke
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

View more
  4 in total

Review 1.  Determination and modelling of stereoselective interactions of ligands with drug transporters: a key dimension in the understanding of drug disposition.

Authors:  P Bhatia; M Kolinski; R Moaddel; K Jozwiak; I W Wainer
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

Review 2.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Mefloquine induces dose-related neurological effects in a rat model.

Authors:  G Dow; R Bauman; D Caridha; M Cabezas; F Du; R Gomez-Lobo; M Park; K Smith; K Cannard
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

4.  Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice.

Authors:  Sylvie Barraud de Lagerie; Emmanuelle Comets; Céline Gautrand; Christine Fernandez; Daniel Auchere; Eric Singlas; France Mentre; François Gimenez
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.